Status
Ongoing
Project acroniem
GEP
Introduction
The genetic profile of breast cancer can be determined using a gene expression profiling (GEP) test. This genetic information provides a better picture of the effectiveness of adjuvant chemotherapy in controlling relapse, enabling unnecessary chemotherapy to be avoided.
Objective
For a specific patient group, namely patients in whom (1) early-stage breast cancer has been diagnosed, (2) who have up to three affected lymph nodes, (3) in whom the tumour is up to five centimetres in size, and (4) who have HER2-, ER+ and/or PR+ after primary surgery without prior therapy, cancer data are registered when a GEP test was requested or performed. These data are registered online by all accredited breast clinics and is a requirement for financial reimbursement by the Rijksinstituut voor Ziekte- en Invaliditeitsverzekering (RIZIV) (National Institute for Health and Disability Insurance) to the breast clinics concerned. The project database contains data for patients belonging to the target group since 1 July 2019.
Financial support and partners
This registration project is run in collaboration with the RIZIV.
Contact
For more information about this registration project, contact gepbreast@kankerregister.org.
The genetic profile of breast cancer can be determined using a gene expression profiling (GEP) test. This genetic information provides a better picture of the effectiveness of adjuvant chemotherapy in controlling relapse, enabling unnecessary chemotherapy to be avoided.
Objective
For a specific patient group, namely patients in whom (1) early-stage breast cancer has been diagnosed, (2) who have up to three affected lymph nodes, (3) in whom the tumour is up to five centimetres in size, and (4) who have HER2-, ER+ and/or PR+ after primary surgery without prior therapy, cancer data are registered when a GEP test was requested or performed. These data are registered online by all accredited breast clinics and is a requirement for financial reimbursement by the Rijksinstituut voor Ziekte- en Invaliditeitsverzekering (RIZIV) (National Institute for Health and Disability Insurance) to the breast clinics concerned. The project database contains data for patients belonging to the target group since 1 July 2019.
Financial support and partners
This registration project is run in collaboration with the RIZIV.
Contact
For more information about this registration project, contact gepbreast@kankerregister.org.
